Ganesh Raghu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1200152/publications.pdf

Version: 2024-02-01

237 papers	47,727 citations	5248 83 h-index	1745 212 g-index
239 all docs	239 docs citations	239 times ranked	19939 citing authors

#	Article	IF	Citations
1	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
2	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	13.9	3,351
3	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134
4	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
5	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
6	Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis. New England Journal of Medicine, 2012, 366, 1968-1977.	13.9	1,353
7	Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 810-816.	2.5	1,113
8	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
9	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
10	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 636-643.	2.5	996
11	Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2011, 365, 1079-1087.	13.9	930
12	An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1004-1014.	2.5	832
13	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
14	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
15	A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2004, 350, 125-133.	13.9	649
16	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 904-910.	2.5	574
17	The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2005, 142, 963.	2.0	530
18	Increased Prevalence of Gastroesophageal Reflux in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1804-1808.	2.5	513

#	Article	IF	Citations
19	Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001â€“11. Lancet Respiratory Medicine,the, 2014, 2, 566-572.	5.2	513
20	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
21	BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 92-99.	2.5	497
22	BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 75-81.	2.5	487
23	Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 729-737.	2.5	481
24	High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 488-493.	2.5	470
25	A new classification system for chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2014, 33, 127-133.	0.3	454
26	Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1061-1069.	2.5	445
27	An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. European Respiratory Journal, 2014, 44, 1479-1503.	3.1	442
28	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
29	Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2093-2101.	13.9	422
30	Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial. The American Review of Respiratory Disease, 1991, 144, 291-296.	2.9	394
31	Rheumatoid Arthritisâ€“Interstitial Lung Diseaseâ€“associated Mortality. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 372-378.	2.5	389
32	The Accuracy of the Clinical Diagnosis of New-Onset Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Disease. Chest, 1999, 116, 1168-1174.	0.4	380
33	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 459-466.	2.5	367
34	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respiratory Medicine,the, 2013, 1, 369-376.	5.2	349
35	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 948-955.	2.5	338
36	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 680-689.	2.5	338

#	Article	IF	Citations
37	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal, 2015, 46, 1113-1130.	3.1	328
38	Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respiratory Medicine,the, 2013, 1, 685-694.	5.2	308
39	Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. European Respiratory Journal, 2016, 48, 1710-1720.	3.1	281
40	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1475-1482.	2.5	257
41	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respiratory Medicine,the, 2020, 8, 171-181.	5.2	253
42	Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease. Chest, 1999, 116, 1175-1182.	0.4	252
43	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1054-1060.	2.5	241
44	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. European Respiratory Journal, 2013, 42, 1622-1632.	3.1	227
45	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	1.0	222
46	Rheumatoid arthritis-associated lung disease. European Respiratory Review, 2015, 24, 1-16.	3.0	220
47	Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18â€“64â€…years old. European Respiratory Journal, 2016, 48, 179-186.	3.1	218
48	Analyses of Efficacy End Points in a Controlled Trial of Interferon-Î³1b for Idiopathic Pulmonary Fibrosis. Chest, 2005, 127, 171-177.	0.4	215
49	The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF. Respiratory Medicine, 2010, 104, 296-304.	1.3	210
50	Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1044-1048.	2.5	209
51	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
52	Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis. Chest, 2006, 129, 794-800.	0.4	206
53	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
54	Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?. American Journal of Medicine, 2010, 123, 304-311.	0.6	183

#	Article	IF	Citations
55	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal, 2014, 44, 1296-1307.	3.1	177
56	Interstitial Lung Disease in India. Results of a Prospective Registry. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 801-813.	2.5	170
57	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2018, 319, 2299.	3.8	170
58	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166
59	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 25-33.	5.2	165
60	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 277-284.	5.2	162
61	Drug Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 756-766.	0.4	155
62	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1481-1491.	3.1	147
63	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	2.5	147
64	Differential Proliferation of Fibroblasts Cultured from Normal and Fibrotic Human Lungs. The American Review of Respiratory Disease, 1988, 138, 703-708.	2.9	143
65	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
66	Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 252-254.	2.5	135
67	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
68	Elevated Transforming Growth Factor-Î± Levels in Bronchoalveolar Lavage Fluid of Patients with Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 424-430.	2.5	121
69	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respiratory Medicine,the, 2019, 7, 487-496.	5.2	119
70	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
71	Interstitial Lung Disease: A Diagnostic Approach: Are CT Scan and Lung Biopsy Indicated in Every Patient?. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 909-914.	2.5	116
72	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respiratory Medicine,the, 2015, 3, 473-482.	5.2	112

#	Article	IF	Citations
73	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	3.1	110
74	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 707-714.	5.2	109
75	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25â€…years. European Respiratory Journal, 2017, 50, 1701209.	3.1	108
76	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105
77	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. European Respiratory Review, 2021, 30, 210011.	3.0	104
78	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity ofÂâ‰50Â% of Predicted Value. Lung, 2016, 194, 739-743.	1.4	102
79	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	2.5	102
80	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 336-347.	2.5	99
81	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal, 2015, 46, 1740-1750.	3.1	97
82	COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respiratory Medicine,the, 2020, 8, 839-842.	5.2	95
83	Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 301-308.	2.5	94
84	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clinical Infectious Diseases, 2016, 62, 313-319.	2.9	92
85	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European Respiratory Review, 2019, 28, 190022.	3.0	89
86	Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) airâ€“lung study. European Respiratory Journal, 2017, 50, 1700559.	3.1	86
87	Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Annals of the American Thoracic Society, 2015, 12, 981-987.	1.5	85
88	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	3.0	82
89	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine, 2016, 14, 18.	2.3	79
90	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine,the, 2017, 5, 61-71.	5.2	79

#	Article	IF	Citations
91	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. Annals of the American Thoracic Society, 2017, 14, 1646-1654.	1.5	77
92	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
93	Polymyositis Associated With Severe Interstitial Lung Disease. Chest, 2011, 139, 441-443.	0.4	74
94	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respiratory Medicine,the, 2019, 7, 657-664.	5.2	73
95	Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1345-1352.	2.5	71
96	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine,the, 2015, 3, 388-396.	5.2	69
97	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.4	66
98	Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1801384.	3.1	66
99	The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. American Journal of Medicine, 2003, 115, 60-64.	0.6	65
100	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk ofÂPulmonary Hypertension Associated With Pulmonary Fibrosis. Chest, 2020, 158, 637-645.	0.4	62
101	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3.	0.8	61
102	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
103	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax, 2016, 71, 1082-1090.	2.7	59
104	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). European Respiratory Journal, 2018, 52, 1801130.	3.1	59
105	Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clinics in Chest Medicine, 2004, 25, 409-419.	0.8	58
106	High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1434-1442.	2.5	58
107	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosisâ€“Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 674-684.	2.5	57
108	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220.	2.5	55

#	Article	IF	Citations
109	Telemedicine â€" maintaining quality during times of transition. Nature Reviews Disease Primers, 2020, 6, 45.	18.1	53
110	Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 129, 24-30.	1.3	52
111	Lung transplantation in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 375-385.	1.0	52
112	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
113	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. European Respiratory Journal, 2016, 48, 826-832.	3.1	47
114	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2017, 196, 1031-1039.	2.5	46
115	Idiopathic Pulmonary Fibrosis: Increased Survival with â€œGastroesophageal Reflux Therapyâ€• American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1330-1332.	2.5	45
116	Idiopathic Interstitial Pneumonia Associated With Autoantibodies. Chest, 2017, 152, 103-112.	0.4	45
117	The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1089-1092.	2.5	45
118	Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1359-1370.	0.4	44
119	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Current Neuropharmacology, 2021, 19, 1202-1224.	1.4	44
120	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2021, 325, 1841.	3.8	43
121	Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSISÂ® trials. Respiratory Research, 2018, 19, 167.	1.4	42
122	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. European Respiratory Journal, 2017, 49, 1601640.	3.1	41
123	Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. International Journal of Cardiology, 2017, 241, 457-462.	0.8	41
124	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41
125	Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?. Respiratory Medicine, 2018, 144, S20-S27.	1.3	38
126	Seasonal Variation. Chest, 2009, 136, 16-22.	0.4	37

#	Article	IF	Citations
127	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	3.1	36
128	Lung transplantation for interstitial lung disease. European Respiratory Review, 2021, 30, 210017.	3.0	36
129	Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. European Respiratory Journal, 2019, 53, 1801699.	3.1	35
130	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
131	Fibrotic interstitial lung diseases and air pollution: a systematic literature review. European Respiratory Review, 2020, 29, 200093.	3.0	33
132	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
133	Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1306-1313.	2.5	32
134	Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 2022, 19, 1193-1202.	1.5	32
135	Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer, 1991, 67, 2407-2409.	2.0	30
136	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European Respiratory Review, 2017, 26, 170071.	3.0	30
137	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72, 472-474.	2.7	29
138	Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1455-1467.	1.5	29
139	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	2.5	29
140	Idiopathic pulmonary fibrosis: current trends in management. Clinics in Chest Medicine, 2004, 25, 621-636.	0.8	28
141	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1256-1262.	0.4	28
142	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. European Respiratory Journal, 2018, 52, 1702106.	3.1	28
143	Hypersensitivity pneumonitis and its correlation with ambient air pollutionÂinÂurban India. European Respiratory Journal, 2019, 53, 1801563.	3.1	27
144	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals of the American Thoracic Society, 2020, 17, 1620-1628.	1.5	27

#	Article	IF	Citations
145	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. European Respiratory Journal, 2016, 47, 1293-1295.	3.1	26
146	Interstitial lung disease before and after COVID-19: a double threat?. European Respiratory Journal, 2021, 58, 2101956.	3.1	26
147	Idiopathic pulmonary fibrosis: tracking the true occurrence is challenging. European Respiratory Journal, 2015, 46, 604-606.	3.1	25
148	Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	2.5	25
149	Human Lung Fibroblast Subpopulations with Different C1q Binding and Functional Properties. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 382-389.	1.4	24
150	Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 1040-1049.	1.5	24
151	Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies. European Respiratory Journal, 2018, 52, 1801485.	3.1	23
152	Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutions. BMC Genomics, 2018, 19, 101.	1.2	23
153	Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 169-178.	1.3	23
154	Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. European Respiratory Review, 2021, 30, 210094.	3.0	23
155	Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. European Respiratory Review, 2021, 30, 210123.	3.0	23
156	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 833-844.	1.5	23
157	Development of Novel Agents for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 1083-1092.	0.4	22
158	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. European Respiratory Journal, 2019, 53, 1801655.	3.1	22
159	Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax, 2020, 75, 78-80.	2.7	22
160	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
161	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. Canadian Journal of Cardiology, 2018, 34, 978-982.	0.8	20
162	2018 Clinical Practice Guideline Summary For Practicing Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2018, 16, 285-290.	1.5	20

#	Article	IF	Citations
163	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. Respiratory Medicine, 2018, 144, S13-S19.	1.3	20
164	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19
165	Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 1030-1039.	1.5	19
166	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
167	The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. European Respiratory Journal, 2015, 46, 883-886.	3.1	18
168	Improving the Standard of Care for Patients With Idiopathic Pulmonary Fibrosis Requires Participation in Clinical Trials. Chest, 2009, 136, 330-333.	0.4	17
169	Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet, The, 2012, 380, 699-701.	6.3	17
170	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
171	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research, 2019, 6, e000443.	1.2	17
172	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
173	Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research, 2022, 23, .	1.4	17
174	Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: the heart burn in patients with IPF can no longer be silent. European Respiratory Journal, 2018, 51, 1800921.	3.1	16
175	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. European Respiratory Journal, 2019, 54, 1900295.	3.1	16
176	Soluble ECM promotes organotypic formation in lung alveolar model. Biomaterials, 2022, 283, 121464.	5.7	16
177	Idiopathic Pulmonary Fibrosis Guideline Recommendations. Need for Adherence to Institute of Medicine Methodology?. Annals of the American Thoracic Society, 2019, 16, 681-686.	1.5	15
178	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Research, 2020, 6, 00152-2020.	1.1	15
179	Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry. Lung India, 2016, 33, 589.	0.3	15
180	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15

#	Article	IF	Citations
181	Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. Respiration, 2020, 99, 625-627.	1.2	14
182	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. Lancet Respiratory Medicine,the, 2017, 5, e1-e2.	5.2	13
183	Reference values for high attenuation areas on chest CT in a healthy, neverâ€smoker, multiâ€ethnic sample: The MESA study. Respirology, 2020, 25, 855-862.	1.3	13
184	Transbronchial Biopsy and Cryobiopsy in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2021, 18, 148-161.	1.5	13
185	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. European Respiratory Journal, 2017, 49, 1602384.	3.1	12
186	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Scientific Reports, 2019, 9, 14802.	1.6	12
187	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1183-1184.	2.5	12
188	Questionnaires or Serum Immunoglobulin G Testing in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Annals of the American Thoracic Society, 2021, 18, 130-147.	1.5	12
189	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine, 2018, 140, 108-114.	1.3	11
190	Associations of ‹b›Ï‰‹/b›-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. American Journal of Epidemiology, 2021, 190, 95-108.	1.6	11
191	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 795-805.	2.5	11
192	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. Expert Review of Respiratory Medicine, 2016, 10, 699-711.	1.0	10
193	Palliative care for patients with pulmonary fibrosis: symptom relief is essential. European Respiratory Journal, 2018, 52, 1802086.	3.1	10
194	Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. Lancet Respiratory Medicine,the, 2019, 7, 926-929.	5.2	10
195	Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians. Annals of the American Thoracic Society, 2021, 18, 559-566.	1.5	10
196	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 2021, , .	1.5	10
197	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	2.5	10
198	Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease. Chest, 2022, 162, 603-613.	0.4	10

#	Article	IF	Citations
199	Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?. European Respiratory Journal, 2019, 53, 1900023.	3.1	9
200	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Research, 2020, 6, 00115-2019.	1.1	9
201	Hypersensitivity Pneumonitis and (Idiopathic) Pulmonary Fibrosis Due to Feather Duvets and Pillows. Archivos De Bronconeumologia, 2021, 57, 87-93.	0.4	9
202	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. Journal of Inflammation, 2021, 18, 17.	1.5	9
203	R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. European Respiratory Journal, 2022, 59, 2100917.	3.1	9
204	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359.	0.3	9
205	Randomized Phase IIa Clinical Study of an Anti-Î±_vÎ²₆Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1166-1168.	2.5	9
206	Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations. European Respiratory Journal, 2017, 49, 1700696.	3.1	8
207	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2020, 382, 779-781.	13.9	8
208	Idiopathic pulmonary fibrosis â€“ clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?. BMC Medicine, 2016, 14, 22.	2.3	7
209	Hypersensitivity pneumonitis: Clinical manifestations â€“ Prospective data from the interstitial lung disease-India registry. Lung India, 2019, 36, 476.	0.3	7
210	Idiopathic pulmonary fibrosis: combating on a new turf. Lancet Respiratory Medicine,the, 2016, 4, 430-432.	5.2	6
211	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. Lancet Respiratory Medicine,the, 2016, 4, e46-e47.	5.2	6
212	Should we be concerned about air quality as a contributor to poor outcomes in lung transplant recipients?. European Respiratory Journal, 2017, 49, 1602369.	3.1	6
213	Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine. European Respiratory Journal, 2021, 57, 2003551.	3.1	6
214	Genome-wide Enrichment of TERT Rare Variants in IPF Patients of Latino Ancestry. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	6
215	Reply: â€œThe ILD-India Registry: Ignoratio Elenchiâ€•and â€œThe ILD-India Registry: Look Before You Leapâ€• American Journal of Respiratory and Critical Care Medicine, 2017, 195, 837-839.	2.5	5
216	Antacid use and subclinical interstitial lung disease: the MESA study. European Respiratory Journal, 2017, 49, 1602566.	3.1	5

#	Article	IF	Citations
217	Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to De Novo Antisynthetase Syndrome. Annals of the American Thoracic Society, 2020, 17, 901-904.	1.5	5
218	Sarcoidosis and idiopathic pulmonary fibrosis: The same tale or a tale of two diseases in one. Respiratory Medicine, 2019, 160, 105668.	1.3	4
219	Diagnosis of idiopathic pulmonary fibrosis by virtual means using â€œIPFdatabaseâ€• a new software. Respiratory Medicine, 2019, 147, 31-36.	1.3	4
220	Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. Lung India, 2021, 38, 5.	0.3	3
221	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. Annals of the American Thoracic Society, 2021, 18, 1839-1848.	1.5	3
222	Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography. Journal of Computer Assisted Tomography, 2019, 43, 109-114.	0.5	2
223	Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal, 2020, 55, 2000590.	3.1	2
224	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
225	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
226	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT â€“ Authors' reply. Lancet Respiratory Medicine,the, 2014, 2, e5-e6.	5.2	1
227	Persistent breathlessness. Lancet, The, 2016, 387, e21.	6.3	1
228	Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists. European Respiratory Journal, 2018, 51, 1800113.	3.1	1
229	Response to Letter to Editor regarding "Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?". Respiratory Medicine, 2019, 149, 43-44.	1.3	1
230	Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine, 2020, 8, 781-781.	0.7	1
231	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. Chest, 2020, 157, 1391-1392.	0.4	1
232	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. European Respiratory Journal, 2020, 55, 1902262.	3.1	1
233	In Reply. Archives of Pathology and Laboratory Medicine, 2021, 145, 1326-1327.	1.2	1
234	Reply to Moodley and to Ravaglia et al.. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 667-669.	2.5	0

#	Article	IF	Citations
235	Reply to MorÃ¡n-Mendoza and Khalil: Are Ground-Glass Opacities on Chest High-Resolution Computed Tomography a Manifestation of Airway Disease?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 781-782.	2.5	0
236	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis. , 2018, , 195-204.		0
237	Reply to: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0